Integra Announces Completion of Refinancing Transactions
Key Highlights
- ➤$450 million 9.500% senior secured notes issued, maturing in 2033
- ➤$1.65 billion credit facility amended and restated
- ➤Credit facility includes $600 million revolver, $600 million term loan A
- ➤$450 million term loan B carries a seven-year maturity
- ➤Proceeds refinanced Integra’s existing credit facility and transaction expenses
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). In addition, Integra announced today that it has amended and restated its existing credit facility, with an overall size of approximately $1.65 billion consisting of (i) a $600 million senior secured revolving credit facility with a five year maturity, (ii) a $600 million senior secured term loan A facility with a five year maturity and (iii) a $450 million senior secured term loan B facility with a seven year maturity (collectively, the “Credit Facility”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Credit Facility.
Get started
Create a free account to read the full story.